

Satoru Kakizaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3117720/publications.pdf>

Version: 2024-02-01

40
papers

702
citations

471061

17
h-index

580395

25
g-index

40
all docs

40
docs citations

40
times ranked

751
citing authors

#	ARTICLE	IF	CITATIONS
1	New Insights on the Xenobiotic-Sensing Nuclear Receptors in Liver Diseases – CAR and PXR-. Current Drug Metabolism, 2008, 9, 614-621.	0.7	81
2	Expression of amino acid transporters (<sc>LAT1</sc>, <sc>ASCT2</sc> and <sc>xCT</sc>) as clinical significance in hepatocellular carcinoma. Hepatology Research, 2015, 45, 1014-1022.	1.8	51
3	Ligand dependent hepatic gene expression profiles of nuclear receptors CAR and PXR. Toxicology Letters, 2012, 212, 288-297.	0.4	42
4	Sofosbuvir+velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatology International, 2018, 12, 356-367.	1.9	41
5	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatology International, 2022, 16, 1150-1160.	1.9	35
6	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatology Research, 2022, 52, 773-783.	1.8	34
7	A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger. Radiotherapy and Oncology, 2019, 132, 230-235.	0.3	31
8	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals, 2021, 14, 36.	1.7	30
9	Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma. BMC Cancer, 2017, 17, 721.	1.1	28
10	Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatology Research, 2020, 50, 382-395.	1.8	28
11	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC stage patients classified as beyond up to seven criteria – Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
12	Does first-line treatment have prognostic impact for unresectable <sc>HCC</sc>? Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
13	Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the <sc>FibroScan</sc> aspartate aminotransferase score. JGH Open, 2021, 5, 1183-1189.	0.7	21
14	A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. Radiation Oncology, 2019, 14, 137.	1.2	20
15	Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatology Research, 2021, 51, 51-61.	1.8	20
16	Xenobiotic-Sensing Nuclear Receptors CAR and PXR as Drug Targets in Cholestatic Liver Disease. Current Drug Targets, 2009, 10, 1156-1163.	1.0	19
17	The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study. Oncology, 2021, 99, 203-214.	0.9	18
18	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. <i>Cancers</i> , 2020, 12, 2906.	1.7	17
20	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	1.8	15
21	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. <i>Internal Medicine</i> , 2021, 60, 2167-2174.	0.3	15
22	Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study. <i>Liver Cancer</i> , 2022, 11, 61-74.	4.2	14
23	Constitutive androstane receptor and pregnane X receptor cooperatively ameliorate DSS-induced colitis. <i>Digestive and Liver Disease</i> , 2019, 51, 226-235.	0.4	13
24	A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 776-783.	0.4	10
25	Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. <i>Oncology</i> , 2021, 99, 641-651.	0.9	9
26	Indirect activation of pregnane X receptor in the induction of hepatic CYP3A11 by high-dose rifampicin in mice. <i>Xenobiotica</i> , 2018, 48, 1098-1105.	0.5	7
27	New endoscopic classification of cascade stomach, a risk factor for reflux esophagitis. <i>Journal of Gastroenterology</i> , 2017, 52, 211-217.	2.3	6
28	Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure. <i>Hepatology Research</i> , 2020, 50, 303-312.	1.8	5
29	The prognosis of elderly patients with hepatocellular carcinoma: A multicenter 19-year experience in Japan. <i>Cancer Medicine</i> , 2023, 12, 345-357.	1.3	5
30	Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe. <i>Hepatology Research</i> , 2021, 51, 303-312.	1.8	4
31	Present status of hepatitis medical care coordinators in regional core centers in Japan. <i>Acta Hepatologica Japonica</i> , 2021, 62, 96-98.	0.0	3
32	A case of chronic hepatitis C accompanied by marked thrombocytopenia during combination therapy with daclatasvir and asunaprevir. <i>Acta Hepatologica Japonica</i> , 2015, 56, 603-609.	0.0	2
33	Minimizing the effect of warfarin potassium during daclatasvir/asunaprevir combination therapy in a case of chronic hepatitis C after aortic dissection. <i>Acta Hepatologica Japonica</i> , 2017, 58, 22-27.	0.0	2
34	A Case of Drug-induced Hypersensitivity Syndrome due to Trichloroethylene. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 598-604.	0.0	2
35	Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. <i>Biomedicines</i> , 2021, 9, 660.	1.4	2
36	Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection. <i>Acta Hepatologica Japonica</i> , 2020, 61, 276-278.	0.0	2

#	ARTICLE	IF	CITATIONS
37	Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately. <i>Internal Medicine</i> , 2021, 60, 3061-3070.	0.3	1
38	Characteristics of cases of hepatitis E in 2019 in Gunma prefecture: a small epidemic caused by the same subgenotype 3a strain. <i>Acta Hepatologica Japonica</i> , 2020, 61, 478-481.	0.0	1
39	IDDF2018-ABS-0110...Efficacy and safety of SOFOSBUVIR/VELPATASVIR plus RIBAVIRIN for 12 or 24 weeks in genotype 1 or 2 HCV-INFECTED japanese patients with prior treatment failure to daa-based regimens. , 2018, , .		0
40	A patient with type I Gaucher disease who switched from enzyme replacement therapy to substrate reduction therapy after having of CYP2D6 polymorphisms checked. <i>Acta Hepatologica Japonica</i> , 2018, 59, 243-251.	0.0	0